Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
181 hedge funds and large institutions have $2.84B invested in Blueprint Medicines in 2018 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 74 increasing their positions, 45 reducing their positions, and 30 closing their positions.
73% more call options, than puts
Call options by funds: $37.1M | Put options by funds: $21.4M
64% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 45
20% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 30
3% more funds holding
Funds holding: 175 → 181 (+6)
2.39% more ownership
Funds ownership: 99.84% → 102.23% (+2.4%)
29% less capital invested
Capital invested by funds: $4B → $2.84B (-$1.16B)
42% less funds holding in top 10
Funds holding in top 10: 12 → 7 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$59.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$23.4M |
| 3 |
CC
Casdin Capital
New York
|
+$22.8M |
| 4 |
Two Sigma Investments
New York
|
+$21.7M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$125M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$61.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$27.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.7M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$22.9M |
BPMC Hedge Fund Activity: Q2 2018 in Review
181 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2018, worth a combined $2.84B — down 29% from $4B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BPMC positions and 30 closed out — a net gain of 6 holders — while 74 added to existing stakes and 45 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $59.1M. The largest seller was TRV GP II, cutting an estimated $125M.
- 181 institutional investors held Blueprint Medicines (BPMC) as of Q2 2018, up from 175 in Q1 2018.
- Funds reported $2.84B of Blueprint Medicines stock for Q2 2018, down 29% quarter-over-quarter.
- 36 funds opened new Blueprint Medicines positions in Q2 2018 and 30 closed out, a net change of +6 holders.
- The largest Blueprint Medicines buyer in Q2 2018 was Fidelity International, an estimated $59.1M added.
- The largest Blueprint Medicines seller in Q2 2018 was TRV GP II, an estimated $125M sold.
Based on aggregated 13F filings for Q2 2018.